Gilead Sciences, Inc.
GILD
$97.00
-$1.16-1.18%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.68% | 6.04% | 3.32% | 1.54% | 1.50% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.68% | 6.04% | 3.32% | 1.54% | 1.50% |
| Cost of Revenue | 1.12% | 3.85% | 8.22% | 11.32% | 9.51% |
| Gross Profit | 5.71% | 6.66% | 2.00% | -1.00% | -0.61% |
| SG&A Expenses | -4.00% | -1.01% | -12.03% | -12.11% | 3.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.32% | 1.45% | -2.96% | 0.14% | 7.40% |
| Operating Income | 16.20% | 14.85% | 15.74% | 4.04% | -8.17% |
| Income Before Tax | 534.88% | -89.93% | -97.55% | -79.06% | -85.21% |
| Income Tax Expenses | 39.38% | -83.09% | -95.53% | -73.49% | -64.29% |
| Earnings from Continuing Operations | 1,202.40% | -91.45% | -98.04% | -81.02% | -91.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -74.47% | -52.38% | -42.22% |
| Net Income | 1,132.44% | -91.53% | -97.86% | -80.80% | -91.33% |
| EBIT | 16.20% | 14.85% | 15.74% | 4.04% | -8.17% |
| EBITDA | 12.79% | 12.13% | 14.30% | 6.40% | -2.50% |
| EPS Basic | 1,144.01% | -91.54% | -97.87% | -80.78% | -91.37% |
| Normalized Basic EPS | 15.25% | 13.53% | 15.39% | 4.83% | -6.80% |
| EPS Diluted | 1,273.20% | -92.09% | -98.39% | -81.49% | -92.21% |
| Normalized Diluted EPS | 15.06% | 13.89% | 15.92% | 5.18% | -6.65% |
| Average Basic Shares Outstanding | -0.08% | -0.08% | -0.16% | -0.28% | -0.38% |
| Average Diluted Shares Outstanding | 0.10% | -0.42% | -0.63% | -0.65% | -0.55% |
| Dividend Per Share | 2.65% | 2.67% | 2.68% | 2.70% | 2.72% |
| Payout Ratio | -0.92% | 11.14% | 46.95% | 4.35% | 10.83% |